For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally living without the crippling sickle cell pain that shaped much of his life.
Louis told reporters that an infusion of his own edited stem cells last March has left him pain-free and able to do everyday things that once triggered brutal crises. CHOP says this was the first time it delivered the newly FDA-approved therapy to a patient outside a clinical trial, a milestone clinicians describe as shifting the treatment from experiment to real-world care.
The procedure collects a patient's stem cells, edits them with CRISPR to switch fetal hemoglobin production back on, then re-infuses the corrected cells so the blood can carry oxygen without sickling.
As reported by CBS Philadelphia, Louis' parents moved the family from New York to South Jersey so they could be closer to CHOP for his follow-up care. His mother called the moment "history in the making."
The story includes comments from Dr. Alexis Thompson, CHOP's chief of hematology, who described the therapy as "extraordinary" and noted that it is particularly meaningful for a population that has often been underserved by the health system. According to CBS, Louis returned to CHOP in March for the infusion of his reconstituted, edited cells and has not experienced the severe vaso-occlusive pain episodes that once dominated his life.
What the Therapy Is and How Well It Works
The treatment, CASGEVY (exagamglogene autotemcel), often shortened to exa-cel, is an individualized, non-viral cell therapy that uses CRISPR/Cas9 to edit a patient's own CD34+ hematopoietic stem cells and increase fetal hemoglobin levels.
Vertex Pharmaceuticals and its partners describe the approach as editing and re-infusing a person's own stem cells so that red blood cells no longer sickle.
Large, pivotal data published in the New England Journal of Medicine showed that most evaluable patients in the trial remained free of severe vaso-occlusive crises for at least 12 consecutive months after infusion.
CHOP's Role and Access
CHOP served as a key site in the multi-center CLIMB studies that tested exa-cel and now processes patients' edited cells in its Cell and Gene Therapy Laboratory, according to the Children's Hospital of Philadelphia.
The manufacturer and its partners are rolling out the therapy through a network of authorized treatment centers, and CRISPR Therapeutics has reported a growing number of activated centers and patients completing stem cell collections.
That broader rollout is what allowed CHOP clinicians to move beyond the original trials and offer the FDA-authorized therapy to eligible patients in routine care.
Who Qualifies and What to Expect
CASGEVY is authorized for people 12 years and older who have recurrent vaso-occlusive crises and requires myeloablative conditioning, a rigorous pre-treatment regimen that suppresses a patient's bone marrow so the edited cells can engraft.
The CLIMB study and follow-up reporting in the New England Journal of Medicine noted that the most serious short-term risks are tied to this conditioning and transplant-style care, including low blood counts and infection risk. Patients also need months of monitoring after infusion.
Clinicians say the trade-off can be profound: for many patients, a durable reduction or even elimination of hospitalizations and pain episodes, at the cost of a highly intensive, resource-heavy treatment pathway.
Louis told CBS Philadelphia that the change in his life has been dramatic, saying, "I feel amazing." CHOP leaders say his experience signals a broader shift as gene editing moves from the research realm into standard care.
The transition brings familiar questions about access, long-term follow-up, and cost, even as it offers a rare chance to end years of suffering for people with sickle cell disease, a condition that disproportionately affects communities of color. CHOP officials say they plan to continue tracking long-term outcomes and expanding capacity through authorized centers as more patients complete the therapy pathway.
